Recent studies have highlighted the pathogenic roles of IL-17–producing CD8+ T cells (T-cytotoxic 17 [Tc17]) in psoriasis. However, the underlying mechanisms of Tc17 induction remain unclear. In this study, we focused on the pathogenic subsets of Th17 and their mechanism of promotion of Tc17 responses. We determined that the pathogenic Th17-enriched fraction expressed melanoma cell adhesion molecule (MCAM) and CCR6, but not CD161, because this subset produced IL-17A abundantly and the presence of these cells in the peripheral blood of patients has been correlated with the severity of psoriasis. Intriguingly, the serial analysis of gene expression revealed that CCR6+MCAM+CD161−CD4+ T cells displayed the gene profile for adaptive immune responses, including CD83, which is an activator for CD8+ T cells. Coculture assay with or without intercellular contact between CD4+ and CD8+ T cells showed that CCR6+MCAM+CD161−CD4+ T cells induced the proliferation of CD8+ T cells in a CD83-dependent manner. However, the production of IL-17A by CD8+ T cells required exogenous IL-17A, suggesting that intercellular contact via CD83 and the production of IL-17A from activated CD4+ T cells elicit Tc17 responses. Intriguingly, the CD83 expression was enhanced in the presence of IL-15, and CD83+ cells stimulated with IL-1β, IL-23, IL-15, and IL-15Rα did not express FOXP3. Furthermore, CCR6+MCAM+CD161−CD4+ T cells expressing CD83 were increased in the peripheral blood of patients, and the CD83+ Th17-type cells accumulated in the lesional skin of psoriasis. In conclusion, pathogenic MCAM+CD161− Th17 cells may be involved in the Tc17 responses via IL-17A and CD83 in psoriasis.
Objective: Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods: In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months one, three, and six. Flow cytometry quantified CD4+CD319+ and CD8+CD319+ T cells, cytotoxic and activation markers, and stimulated intracellular interleukin‐4 (IL‐4), IL‐17A, and interferon‐γ (IFN‐γ). Analyses compared abatacept‐treated molecular endotypes with placebo and related immune changes to modified Rodnan skin score (mRSS) change. Skin single‐cell RNA sequencing included five healthy controls and eight patients with SSc. Results: At baseline, CD319+ T cells showed greater cytokine production, activation, and granzyme and perforin expression than CD319− T cells in 60 evaluable participants ( P < 0.001 to P < 0.0001). Abatacept reduced CD4+CD319+ and CD8+CD319+ T cell frequencies at month six; placebo did not. Effects were strongest in patients in the fibroproliferative group, in whom CD8+CD319+ T cells decreased versus placebo (n = 7 versus n = 36; P = 0.0377). In this endotype, abatacept reduced IL‐4 in CD4+CD319+ and CD8+CD319+ T cells at month three ( P = 0.0468 and P = 0.0287) and IL‐17A in CD8+CD319+ T cells at month six ( P = 0.0004), whereas IFN‐γ was unchanged. Reduction in CD4+CD319+ T cells correlated with mRSS improvement in abatacept‐treated patients (r = 0.5297, P = 0.0423). Skin single‐cell RNA sequencing showed increased SLAMF7 expression in SSc T cells ( P = 0.017), enriched within cytotoxic subsets. Conclusion: CD319+ T cells represent highly differentiated, activated cytotoxic effector populations in SSc. Abatacept selectively modulates these cells and suppresses associated profibrotic and proinflammatory cytokines, particularly in the fibroproliferative subtype, in which CD319+ T cell reductions correlate with clinical improvement. image
Rheumatoid arthritis (RA), a chronic autoimmune condition, causes irreversible bone destruction. A disintegrin and metalloprotease 10 (ADAM-10) has been implicated in inflammatory processes in RA. We investigated the potential role of ADAM-10 in osteoblast mineralization and RA-associated bone destruction. Serum ADAM-10 levels in RA patients were measured by ELISA, and ADAM-10 expression in osteoblasts was assessed by Western blotting. Collagen-induced arthritis (CIA) mice were treated intraperitoneally with the ADAM-10 inhibitor GI254023X (100 mg/kg) for three weeks. Arthritis and bone destruction were evaluated by macroscopic, immunohistochemical, histological, and micro-CT analyses. The effects of ADAM-10 inhibition on primary osteoblast mineralization were also assessed by Alizarin Red S staining. Serum ADAM-10 levels in patients with RA tended to be higher at Stage III of the Steinbrocker classification. In CIA mice, ADAM-10 inhibition attenuated weight loss, paw swelling, and arthritis scores and suppressed bone destruction. ADAM-10 inhibition also significantly reduced Rankl expression in knee joints. Furthermore, the inhibition reversed the suppression of primary osteoblast mineralization induced by TNF-α. Pharmacological inhibition of ADAM-10 attenuated experimental arthritis and bone destruction and improved osteoblast mineralization, suggesting that ADAM-10 may contribute to inflammatory bone destruction in RA.